Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works by Trautmann, Michael E.
Results: 12
1
2
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
- Published in:
- 2007
- By:
- Publication type:
- journal article
3
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes.
- Published in:
- Annals of Internal Medicine, 2007, v. 146, n. 7, p. 477, doi. 10.7326/0003-4819-146-7-200704030-00003
- By:
- Publication type:
- Article
4
53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-53-OR
- By:
- Publication type:
- Article
5
1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1023-P
- By:
- Publication type:
- Article
6
1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1014-P
- By:
- Publication type:
- Article
7
1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1001-P
- By:
- Publication type:
- Article
8
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1292, doi. 10.1111/dom.14032
- By:
- Publication type:
- Article
9
Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1176, doi. 10.1111/dom.14020
- By:
- Publication type:
- Article
10
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2429, doi. 10.1111/dom.13824
- By:
- Publication type:
- Article
11
Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post‐hoc analysis of the DURATION‐3 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 1049, doi. 10.1111/dom.13606
- By:
- Publication type:
- Article
12
Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment.
- Published in:
- Diabetes, 1997, v. 46, n. 2, p. 265, doi. 10.2337/diab.46.2.265
- By:
- Publication type:
- Article